Cervical cancer vaccine in final testing stage
Published: June 27, 2005
A vaccine developed by scientists at the University of Rochester Medical Centre to prevent cervical cancer is in the final stages of testing, says a report in the university website.
After more than a decade of research, Richard Reichman and two other scientists have developed the vaccine, which targets a group of viruses known as human papillomaviruses (HPV).
Amazon discount!
The Official Patient’s Sourcebook on Cervical Cancer: A Revised and Updated Directory for the Internet AgeThe virus causes 12,000 cases of cervical cancer in women in the United States annually. Cervical cancer kills more than 250,000 women around the globe every year.
The toll is much worse in other parts of the world, where Pap smears to detect the disease in its earliest stages are not widely available. In some parts of the world, cervical cancer is the leading cause of death of women, it said.
The vaccine, expected to become available within a year or two, is in the final stages of testing in studies by two companies, Merck and Co and GlaxoSmithKline
If you enjoyed this good news Subscribe to Good News Blog
Share this
To share this simply copy and paste one of the below URL's: